Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance

Cancer Research

Volumn 70, Issue 21, 2010, Pages 8726-8735

  Huo, Hairong ^a   Magro, Pellegrino G ^a   Christy Pietsch, E ^b   Patel, Brijesh B ^a   Scotto, Kathleen W ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; CCAAT BINDING FACTOR; HISTONE ACETYLTRANSFERASE PCAF; HISTONE METHYLTRANSFERASE; MESSENGER RNA; MIXED LINEAGE LEUKEMIA 1 PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEAR FACTOR Y; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CYTOTOXICITY; DOWN REGULATION; EPIGENETICS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; WESTERN BLOTTING;

ACETYLATION; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CCAAT-BINDING FACTOR; CELL PROLIFERATION; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HELA CELLS; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; KIDNEY; LUCIFERASES; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; P-GLYCOPROTEIN; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 78449290132     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0755     Document Type: Article

References (50)

1. Lennartsson A, Ekwall K. Histone modification patterns and epigenetic codes. Biochim Biophys Acta 2009;1790:863-8.
2. Berger SL. The complex language of chromatin regulation during transcription. Nature 2007;447:407-12.
3. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007;128:707-19.
4. Eckford PD, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 2009;109:2989-3011.
5. Stavrovskaya AA, Stromskaya TP. Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry (Moscow) 2008;73:592-604.
6. Sakaeda T, Nakamura T, Hirai M, et al. MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling. Pharm Res 2002;19: 1323-9.
7. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000;22:137-40.
8. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008;38:802-32.
9. Mizutani T, Masuda M, Nakai E, et al. Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab 2008;9:167-74.
10. Aye IL, Singh AT, Keelan JA. Transport of lipids by ABC proteins: interactions and implications for cellular toxicity, viability and function. Chem Biol Interact 2009;180:327-39.
11. Jin S, Scotto KW. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 1998;18:4377-84.
12. Hu Z, Jin S, Scotto KW. Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1. J Biol Chem 2000;275: 2979-85.
13. Baker EK, Johnstone RW, Zalcberg JR, El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 2005;24:8061-75.
14. Ruthenburg AJ, Allis CD, Wysocka J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell 2007;25:15-30.
15. Shilatifard A. Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr Opin Cell Biol 2008; 20:341-8.
16. Xia ZB, Popovic R, Chen J, et al. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. Proc Natl Acad Sci U S A 2005;102:14028-33.
17. Mantovani R, Li XY, Pessara U, Hooft van Huisjduijnen R, Benoist C, Mathis D. Dominant negative analogs of NF-YA. J Biol Chem 1994; 269:20340-6.
18. Ramirez-Carrozzi VR, Nazarian AA, Li CC, et al. Selective and antagonistic functions of SWI/SNF and Mi-2β nucleosome remodeling complexes during an inflammatory response. Genes Dev 2006; 20:282-96.
19. Liu H, Cheng EH, Hsieh JJ. Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. Genes Dev 2007; 21:2385-98.
20. Swift S, Lorens J, Achacoso P, Nolan GP. Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Curr Protoc Immunol 2001. Chapter 10:Unit 10.17C.
21. Ringrose L, Paro R. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet 2004;38: 413-43.
22. Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 1995; 378:505-8.
23. Yokoyama A, Kitabayashi I, Ayton PM, Cleary ML, Ohki M. Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties. Blood 2002;100:3710-8.
24. Hsieh JJ, Ernst P, Erdjument-Bromage H, Tempst P, Korsmeyer SJ. Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization. Mol Cell Biol 2003;23:186-94.
25. Milne TA, Briggs SD, BrockHW, et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 2002;10:1107-17.
26. Terranova R, Agherbi H, Boned A, Meresse S, Djabali M. Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll. Proc Natl Acad Sci U S A 2006;103: 6629-34.
27. Guenther MG, Jenner RG, Chevalier B, et al. Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci U S A 2005; 102:8603-8.
28. Milne TA, Dou Y, Martin ME, Brock HW, Roeder RG, Hess JL. MLL associates specifically with a subset of transcriptionally active target genes. Proc Natl Acad Sci U S A 2005;102:14765-70.
29. Wang P, Lin C, Smith ER, et al. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol Cell Biol 2009;29:6074-85.
30. Lim DA, Huang YC, Swigut T, et al. Chromatin remodeling factor Mll1 is essential for neurogenesis from postnatal neural stem cells. Nature 2009;458:529-33.
31. Mishra BP, Ansari KI, Mandal SS. Dynamic association of MLL1, H3K4 trimethylation with chromatin and Hox gene expression during cell cycle. FEBS J 2009;276:1629-40.
32. Scotto KW, Johnson RA. Transcription of the multidrug resistance gene MDR1: a therapeutic target. Mol Interv 2001;1:117-25.
33. Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene 2003;22:7496-511.
34. Okamura H, Yoshida K, Sasaki E, Morimoto H, Haneji T. Transcription factor NF-Y regulates mdr1 expression through binding to inverted CCAAT sequence in drug-resistant human squamous carcinoma cells. Int J Oncol 2004;25:1031-7.
35. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications, and leukaemia stem-cell development. Nat Rev Cancer 2007;7:823-33.
36. 2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux. Cytometry 1996;25:14-20.
37. Liedtke M, Cleary ML. Therapeutic targeting of MLL. Blood 2009; 113:6061-8.
38. Chen CS, Sorensen PH, Domer PH, et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 1993;81:2386-93.
39. Jiang C, Pugh BF. Nucleosome positioning and gene regulation: advances through genomics. Nat Rev Genet 2009;10:161-72.
40. Donati G, Gatta R, Dolfini D, Fossati A, Ceribelli M, Mantovani R. An NF-Y-dependent switch of positive and negative histone methyl marks on CCAAT promoters. PloS One 2008;3:e2066.
41. Li J, Lin Q, Yoon HG, et al. Involvement of histone methylation in regulation of transcription by thyroid hormone receptor. Mol Cell Biol 2002;22:5688-97.
42. Nightingale KP, Gendreizig S, White DA, Bradbury C, Hollfelder F, Turner BM. Cross-talk between histion modifications in response to histone deacetylase inhibitors: MLL4 links histone H3 acetykation and histone H3K4 methylation. J Biol Chem 2007;282:4408-16.
43. Reddy KS, Parsons L, Mark L, et al. Segmental amplification of 11q23 region identified by fluorescence in situ hybridization in four patients with myeloid disorders: a review. Cancer Genet Cytogenet 2001;126:139-46.
44. Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005;121:167-78.
45. Zeisig BB, Cheung N, Yeung J, So CW. Reconstructing the disease model an epigenetic networks for MLL-AF4 leukemia. Cancer Cell 2008;14:345-7.
46. Krivtsov AV, Feng Z, Lemieux ME, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008;14: 355-68.
47. Guenther MG, Lawton LN, Rozovskaia T, et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev 2008;22:3403-8.
48. Kourti M, Vavatsi N, Gombakis N, et al. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int J Hematol 2007;86:166-73.
49. Dhooge C, De Moerloose B, Laureys G, et al. Expression of the multi-drug transporter P-glycoprotein is highly correlated with clinical outcome in childhood acute lymphoblastic leukemia: results of a long-term prospective study. Leuk Lymphoma 2002;43:309-14.
50. Marie JP, Legrand O. MDR1/P-GP expression as a prognostic factor in acute leukemias. Adv Exp Med Biol 1999;457:1-9.